Atyr PHARMA INC (NASDAQ:ATYR) Receives $19.25 Average Price Target from Analysts

Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $18.60.

A number of research analysts have issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They issued an "overweight" rating for the company. HC Wainwright reissued a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday. Finally, Leerink Partners began coverage on shares of Atyr PHARMA in a report on Tuesday. They set an "outperform" rating and a $16.00 target price for the company.

Atyr PHARMA Stock Performance

Shares of NASDAQ ATYR traded down $0.11 during midday trading on Tuesday, reaching $4.32. The company had a trading volume of 1,767,908 shares, compared to its average volume of 987,059. The business's 50-day simple moving average is $3.61 and its 200 day simple moving average is $2.87. The stock has a market cap of $362.63 million, a P/E ratio of -4.60 and a beta of 1.10. Atyr PHARMA has a 1 year low of $1.42 and a 1 year high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.

Institutional Trading of Atyr PHARMA

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company's stock valued at $55,000 after buying an additional 10,754 shares during the period. Alterna Wealth Management Inc. acquired a new stake in Atyr PHARMA during the fourth quarter valued at $36,000. Kingswood Wealth Advisors LLC acquired a new stake in Atyr PHARMA during the fourth quarter valued at $170,000. American Century Companies Inc. acquired a new stake in Atyr PHARMA during the fourth quarter valued at $319,000. Finally, Raymond James Financial Inc. acquired a new stake in Atyr PHARMA during the fourth quarter valued at $39,000. Institutional investors and hedge funds own 61.72% of the company's stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.